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We report that the mitochondrial chaperone TRAP1,
which is induced in most tumor types, is required
for neoplastic growth and confers transforming
potential to noncancerous cells. TRAP1 binds to
and inhibits succinate dehydrogenase (SDH), the
complex II of the respiratory chain. The respiratory
downregulation elicited by TRAP1 interaction with
SDH promotes tumorigenesis by priming the succi-
nate-dependent stabilization of the proneoplastic
transcription factor HIF1a independently of hypoxic
conditions. These findings provide a mechanistic
clue to explain the switch to aerobic glycolysis of
tumors and identify TRAP1 as a promising antineo-
plastic target.
INTRODUCTION
Tumors undergo sustained growth in a dynamic environment
where oxygen and nutrients are often scarce (Denko, 2008;
Hanahan and Weinberg, 2011). To cope with the energetic
requirements of rapid proliferation in these challenging condi-
tions (Fritz and Fajas, 2010), tumor cells profoundly reorganize
their core metabolism (Cairns et al., 2011; Levine and Puzio-
Kuter, 2010). Glucose utilization, which provides ATP, essential
anabolic intermediates, and antioxidative defenses (Hsu and Sa-
batini, 2008; Vander Heiden et al., 2009), is boosted and dissoci-
ated fromoxygen availability (theWarburg effect;Warburg, 1956;
Warburg et al., 1927). Key to theWarburg effect is the decrease of
mitochondrial respiration (Frezza and Gottlieb, 2009), which
allows cancer cells to grow in the hypoxic conditions found in
the interior of the tumor mass (Hsu and Sabatini, 2008).
Themolecular mechanisms that inhibit oxidative phosphoryla-
tion (OXPHOS) in tumors are understood only partially. The tran-988 Cell Metabolism 17, 988–999, June 4, 2013 ª2013 Elsevier Inc.scription factor HIF1 (hypoxia-inducible factor 1) decreases the
flux of pyruvate into the Krebs cycle and, hence, the flow of
reducing equivalents needed to power the electron transport
chain (ETC) and stimulates glycolysis by inducing glucose trans-
porters and glycolytic enzymes (Denko, 2008; Semenza, 2010b).
HIF is activated by hypoxia as well as by the accumulation of the
Krebs cycle metabolites succinate and fumarate that inhibit the
prolyl hydroxylases (PHDs) responsible for proteasomal degra-
dation of the HIF1a subunit (Selak et al., 2005). Succinate accu-
mulation can originate from loss-of-function mutations in any of
the genes encoding for succinate dehydrogenase (SDH) sub-
units (or their assembly factor SDHAF2), which cause hereditary
paraganglioma-pheochromocytoma syndrome and are associ-
ated to a number of other neoplasms (Bardella et al., 2011).
Within this conceptual framework, we have analyzed the activ-
ity of TRAP1, an evolutionarily conserved chaperone of the
Hsp90 family mainly located in the mitochondrial matrix and
overexpressed in a variety of tumor cell types, where it exerts
antiapoptotic functions through mechanisms that are only
partially understood (Altieri et al., 2012; Kang et al., 2007). Our
results indicate that TRAP1 supports tumor progression by
downmodulating mitochondrial respiration through a decrease
in the activity of SDH, which leads to HIF1a stabilization even
in the absence of hypoxic conditions, by increasing succinate
levels.
RESULTS
Mitochondrial TRAP1 Promotes Neoplastic
Transformation
We found that TRAP1 is localized in mitochondria of cancer cell
models (Figures S1A and S1B available online), as expected
(Altieri et al., 2012), and that downregulation of TRAP1 expres-
sion by RNAi abrogated any transforming potential. In fact,
knockdown of TRAP1 expression made SAOS-2 osteosarcoma
cells, HCT116 colon carcinoma cells, and HeLa cervix carci-
noma cells (dubbed shTRAP1 cells; Figures S1C–S1E) unable
Figure 1. TRAP1 Knockdown Inhibits In Vitro and In Vivo Neoplastic Transformation
(A and B) Human osteosarcoma SAOS-2 cells, human colorectal carcinoma HCT116 cells, and human cervix carcinomaHeLa cells lose the capability to form foci
(A) or colonies in soft agar (B) after knocking down TRAP1 expression. Cells stably transfected with a scrambled shRNA or with TRAP1 shRNAs are dubbedmock
and shTRAP1, respectively. Data indicate the total focus or colony area at the 25th experimental day. Representative areas showing focus or colony growth are
reported.
(C) Rate of growth of mock and shTRAP1 SAOS-2, HCT116, and HeLa cells.
(D) Kinetics of tumor growth in nudemice after injection of SAOS-2 cells without or with aMatrigel bolus (left and right, respectively); representative tumors grown
with Matrigel are shown on the right. Data are reported as mean ± SD values (nR 3).
Cell Metabolism
TRAP1 Promotes Neoplastic Growth by Inhibiting SDHto both form foci (Figure 1A) and grow in soft agar (Figure 1B)
without affecting the rate of cell growth (Figure 1C). Notably,
shTRAP1 tumor cells lost the ability to develop tumor masses
when injected into nude mice (Figure 1D).CConversely, when the TRAP1 complementary DNA (cDNA)
was expressed in either RWPE-1 prostate epithelial cells or fibro-
blasts, these nontransformed cells acquired the capacity to form
colonies in soft agar (Figures 2A and 2D), and downregulation ofell Metabolism 17, 988–999, June 4, 2013 ª2013 Elsevier Inc. 989
Figure 2. Mitochondrial TRAP1 Confers
Transforming Potential to Cells
(A and B) Soft agar tumorigenesis assays were
performed both in nontransformed cells (i.e.,
human epithelial prostate RWPE-1 cells) (A) and
MEFs (D), stably transfected with either a TRAP1
cDNA or with a scrambled shRNA (mock); and in
transformed cells, i.e., human epithelial prostate
RWPE-2 cells obtained by v-Ki-Ras expression in
RWPE-1 cells (B); cells dubbed shTRAP1a and
shTRAP1b were transfected with different TRAP1
shRNAs.
(C) Expression of a mouse TRAP1 cDNA
(mTRAP1) insensitive to human-directed shTRAP1
constructs reinstated the capability to form foci in
human osteosarcoma SAOS-2 cells stably trans-
fected with TRAP1 shRNAs (shTRAP1).
(D and E) Growth of colonies in soft agar was also
assessed in MEF cells (D) or in SAOS-2 shTRAP1
cells (E) stably transfected with a TRAP1 construct
lacking the mitochondrial import sequence
(DNTRAP1). Western immunoblots show TRAP1
expression levels in the different cell types;
GAPDH or actin are shown as loading controls. In
(D) and (E), the cytosolic localization of DNTRAP1
was assessed by subcellular fractionation; cas-
pase-3 and cyclophilin D (CyP-D) are used to verify
purity of cytosolic and mitochondrial fractions,
respectively. Data are reported as mean ± SD
values (nR 3).
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formed by expression of v-Ki-Ras in RWPE-1 cells (Rasola
et al., 2010a), abolished their tumorigenic features (Figure 2B).
Moreover, stable transfection of a murine TRAP1 cDNA, which
is insensitive to human-directed small hairpin RNA (shRNA)
constructs, reinstalled the tumorigenic capability of shTRAP1
cells (Figure 2C). Mitochondrial localization of TRAP1 was
essential for its proneoplastic activity, as expression of a
TRAP1 cDNA devoid of its mitochondrial targeting sequence
was not tumorigenic in either cancer or nontransformed cells
(Figures 2D and 2E).
TRAP1 Binds SDH and Inhibits its Succinate:Coenzyme
Q Reductase Enzymatic Activity
We then asked whether TRAP1 promotes transformation by
acting on mitochondrial metabolism, thus contributing to the
Warburg phenotype. This could occur through an inhibitory
effect on respiration. We used a blue native (BN)-PAGE
approach (Figure 3A), which allows the separation and charac-
terization of protein complexes under nondenaturing conditions
(Wittig and Scha¨gger, 2008), to investigate a possible interaction
between TRAP1 and ETC complexes. By cutting BN-PAGE
bands and running them on an SDS-PAGE, we could observe
the association between TRAP1 and both complex IV (cyto-
chrome oxidase, COX) and complex II (succinate dehydroge-
nase, SDH) (Figure 3A). Moreover, by performing an immunoblot
directly on the BN-PAGE, we found TRAP1 to be in correspon-
dence with both complex IV and complex II bands; notably,
these bands were diffused, and TRAP1 colocalized with their
upper portion, suggesting that TRAP1 contributes to form a mul-
timeric complex of higher molecular weight than the ETC com-
plex per se (Figure 3B). We confirmed the interaction between990 Cell Metabolism 17, 988–999, June 4, 2013 ª2013 Elsevier Inc.TRAP1 and complex II/SDH through further approaches,
including (1) immunoprecipitation, finding coimmunoprecipita-
tion (coIP) of TRAP1 with SDH and vice versa (Figure 3C), and
(2) mitochondrial protein crosslinking with dimethyl 3,30-dithio-
bis-propionimidate (DTBP), a homobifunctional compound that
reacts with the primary amines of two interacting proteins at an
average distance of about 8 A˚ (Giorgio et al., 2009), followed
by TRAP1 immunoprecipitation in order to determine whether
TRAP1 and SDH are closely associated. We found that two
TRAP1/SDH complexes are formed in mitochondria (Figure 3D).
We then measured whether TRAP1 affects complex II enzy-
matic activity. Complex II couples the Krebs cycle to OXPHOS
by oxidizing succinate to fumarate and then transferring elec-
trons to coenzyme Q; hence, the enzyme is called either SDH
or succinate:coenzyme Q reductase (SQR; Cecchini, 2003;
Lemarie and Grimm, 2011). SQR activity can be assessed spec-
trophotometrically in permeabilized mitochondria after inhibition
of the other ETC complexes by recording the reduction of 2,6-
dichlorophenolindophenol (DCPIP) in the presence of succinate
as an electron donor and coenzyme Q1 as an intermediate elec-
tron acceptor. The slope of the absorbance decline of DCPIP is
directly proportional to SQR activity (see Figure S2A). We found
that SQR enzymatic activity was increased in mitochondria from
shTRAP1 cells relative to those derived from control cells (Fig-
ures 4A, S2A, and S2B). TRAP1 did not affect either the cyto-
chrome oxidase enzymatic activity of complex IV (Figure S2C)
or complex II protein levels (Figure S2D) or mitochondrial mass
(Figure S2E). Specificity of TRAP1 inhibition on SDH was
assessed by (1) expression of the mouse TRAP1 (in shTRAP1
cells) that is insensitive to human-directed shTRAP1 constructs,
which resulted in inhibition of SQR activity to values similar to
those of mock cells (Figure 4A), and (2) using an inhibitor of
Figure 3. TRAP1 Binds to ETC Complexes IV and II
(A) Blue native gel electrophoresis. Bands corresponding to complex IV
(cytochrome oxidase, COX) and complex II (succinate dehydrogenase, SDH)
were cut, run on a SDS-PAGE, and probed with anti-TRAP1, anti-COX subunit
II (COXII), and anti-SDH subunit B (SDHB) antibodies.
(B) Western immunoblotting was performed directly on a BN-PAGE. Probing
was carried out with an anti-TRAP1 antibody and, in parallel lanes, with either
an anti-COXII or an anti-SDH subunit A (SDHA) antibody. Note the smeared
signal of both COXII and SDHA, suggesting that a population of complexes II
and IV is present in the BN-PAGE; TRAP-1 is in the upper part of each complex
band.
(C) Complex II and TRAP1 immunoprecipitations (IPs) on lysates of SAOS-2
mock cells. The interaction between TRAP1 and SDHA is shown by coIP.
Immunoglobulin G (IgG) is used in negative isotype controls.
(D) Crosslinking experiments on mitochondria from mock SAOS-2 cells.
TRAP1 was immunoprecipitated after mitochondrial treatment with the
crosslinker DTBP, loaded in parallel on separate lanes of an SDS-PAGE, and
probed with either an anti-TRAP1 or an anti-SDHA antibody.
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TRAP1 Promotes Neoplastic Growth by Inhibiting SDHTRAP1/Hsp90 ATPase activity (Felts et al., 2000), 17-allylamino-
17-demethoxygeldanamycin (17-AAG), whose availability to
mitochondria was recently shown in situ (Xie et al., 2011);
17-AAG specifically increased SQR activity in control mitochon-
dria, whereas shTRAP1 mitochondria were insensitive to the
drug (Figures 4A, 4B, and S2B). Notably, the effect of 17-AAG
was unrelated to Hsp90, as Hsp90 protein levels were the
same in mock and shTRAP1 cells (Figure S2F). The SQR activity
of ETC complex II was further inhibited inmitochondria from con-
trol cells that progressed through the focus-forming assay
compared to mitochondria from the same cells kept in standard
culture conditions, whereas no change in SQR activity could be
appreciated in mitochondria from shTRAP1 cells during theCfocus-forming experiments (Figure 4B). 17-AAG could still reac-
tivate the SDH enzyme in mitochondria of TRAP1-expressing
cells undergoing the focus-forming process (Figure 4B), indi-
cating that even the enhanced inhibition of SQR activity occur-
ring during the in vitro transformation progression is mediated
by TRAP1 and remains reversible. In further accord with an inhib-
itory function of TRAP1 on ETC complex II, mitochondria from
MEF cells stably expressing TRAP1 showed a diminished SQR
activity compared to controls, and this inhibition was increased
during the focus-forming assay; 17-AAG reactivated SDH selec-
tively in mitochondria from TRAP1-expressing MEFs (Figure 4C).
TRAP1 Induction Inhibits Complex II Enzymatic Activity
in Human Colorectal Cancers
TRAP1 expression was shown to be increased in a variety of
tumor types (Kang et al., 2007 and http://www.proteinatlas.
org/). We analyzed the SQR activity of ETC complex II in a set
of human colorectal cancer samples and compared it with that
measured in the surrounding nontransformed mucosa for each
patient. In all colorectal cancer samples at stage IV, character-
ized by metastases to lymph nodes and to distant sites, and in
the majority of samples of stage I–III, characterized by the
absence of distant metastases, TRAP1 was upregulated relative
to normal mucosa (Costantino et al., 2009). When we measured
SQR activity in extracts from these samples, we found that
TRAP1 upregulation was always paralleled by a decrease in
SQR activity, and that this decrease could be partially rescued
by adding 17-AAG before starting recordings (Figure 4D). In a
small subset of stage I–III colorectal cancers, TRAP1 expression
was not induced relative to surrounding nontumor tissues. In
these samples, we could not detect any difference in SQR activ-
ity between samples from tumor and normal mucosa (Figure 4E),
strengthening the link between TRAP1 and the regulation of
complex II activity.
TRAP1 Inhibits Cell Oxygen Consumption Rate and ATP
Production by OXPHOS
The SQR assays described so far measure the maximal enzy-
matic activity of complex II, as the complex is made accessible
in permeabilizedmitochondria and exposed to an excess of sub-
strates. We next analyzed whether TRAP1 also affects the oxy-
gen consumption rate (OCR) of living cells. Downregulation of
TRAP1 markedly increased mitochondrial-dependent respira-
tion in all cancer cell models we tested (Figures 5A, S3A, and
S3B); in full accord with the effect of the drug on SQR activity
(see Figure 4A), the TRAP1 inhibitor 17-AAG increased OCR
only in TRAP1-expressing cells (Figure S4A). In shTRAP1 cells,
the extra OCR was used to make ATP, as it was inhibited
by the ATP synthase blocker oligomycin; moreover, addition of
the uncoupler FCCP increased respiration well above the basal
level, indicating an increased respiratory capacity that remained
fully sensitive to ETC inhibition by rotenone (Figure 5A). The com-
parison with control cells is striking because, unlike shTRAP1
cells, they already utilize their maximal respiratory capacity
under basal conditions, as shown by the lack of OCR increase
with FCCP (Figure 5A), an arrangement implying that any addi-
tional ATP requirement must be provided by glycolysis. Consis-
tently, we found that OXPHOS marginally contributes to ATP
synthesis in mock cells, whereas a high proportion of theell Metabolism 17, 988–999, June 4, 2013 ª2013 Elsevier Inc. 991
Figure 4. TRAP1 Downregulates the Enzymatic Activity of RC Complex II
(A and B) Analysis of the SQR enzymatic activity of complex II inmitochondria fromSAOS-2 cells. In (A), analysis is performed onmitochondria from cultured cells;
in (B), complex II activity values of mitochondria from cultured cells are compared with mitochondrial extracts from focus-forming assays obtained at the 15th
experimental day (i.e., 1–2 days before cells that did not form foci massively underwent death). Mock indicates SAOS-2 cells stably transfected with a scrambled
shRNA; shTRAP1 indicates SAOS-2 cells stably transfected with a TRAP1 shRNA; shTRAP1 + mTRAP1 indicates SAOS-2 shTRAP1 cells transfected with a
mouse TRAP1 cDNA insensitive to human-directed shTRAP1 constructs (see Figure 2C). Enzyme activity values are compared to those of SAOS-2 mock cells in
culture.
(C) SQR activity is measured onmitochondria fromMEFs kept in culture or undergoing a focus-forming assay (15th day). TRAP1 indicates cells stably transfected
with the TRAP1-containing vector; cells stably transfected with a control vector are dubbedmock. Enzyme activity values are compared to those of mitochondria
from TRAP1-expressing MEFs in culture. TRAP1 inhibitor 17-AAG was added 5 min before starting recordings. Bar graphs report mean ± SD values (nR 3);
*p < 0.01 with a Student’s t test analysis.
(D and E) Representative analyses of SQR activity on human colorectal cancer (CRC) samples are compared to surrounding noncancerous mucosae of the same
patient. As shown in the insets, TRAP1 expression was compared between each CRC and noncancerous mucosa by western immunoblot followed by densi-
tometric analysis normalized to GAPDH, which was used as a loading control. TRAP1 was considered induced when the ratio of the protein level between tumor
sample and surrounding noncancerous mucosa wasR 3. Samples reported in (D) were obtained frommetastatic CRC tumors and display an increase of TRAP1
expression in tumors with respect to mucosae; samples reported in (E) were obtained from nonmetastatic CRC tumors and do not show any relevant increase of
TRAP1 expression.
Cell Metabolism
TRAP1 Promotes Neoplastic Growth by Inhibiting SDHintracellular ATP content is provided by glycolysis, with amarked
increase of glycolytic ATP during the in vitro tumorigenic pro-
cess; instead, in shTRAP1 cells, most of the ATP comes from
OXPHOS (Figure 5B). Moreover, expression of the TRAP1
cDNA in nontransformed fibroblasts markedly inhibited basal
OCR and abolished any respiratory reserve (Figure 5C),
mimicking the respiratory pattern of TRAP1-expressing tumor
cells. Expression in shTRAP1 cells of the murine TRAP1 insensi-
tive to human-directed shTRAP1 constructs determined an OCR
pattern indistinguishable from that of mock cells (Figure 5D).992 Cell Metabolism 17, 988–999, June 4, 2013 ª2013 Elsevier Inc.SDH Inhibitors Selectively Affect Respiration, Survival,
and Soft Agar Growth in shTRAP1 Cells
A low concentration of the ETC complex II inhibitors 3-nitropro-
pionic acid (3-NP), which inactivates SDH after covalent binding
with an Arg residue in the catalytic core of SDHA (Huang et al.,
2006), or thenoyltrifluoroacetone (TTFA), which blocks electron
transfer from succinate to coenzyme Q at the quinone-binding
site in subunits B and D (Huang et al., 2006), inhibited OCR in
shTRAP1 cells but were inactive in the presence of TRAP1 (Fig-
ures S4B and S4C), paralleling the downmodulation of the SQR
Figure 5. TRAP1-Induced Downmodulation of SDH Activity Decreases Cell Oxygen Consumption Rate and OXPHOS-Dependent Synthesis
of ATP and Prompts Resistance to Stress Stimuli
(A) Representative traces of OCR experiments performed on monolayers of living SAOS-2 cells. Subsequent additions of the ATP synthase inhibitor oligomycin,
the uncoupler FCCP, the ETC complex I inhibitor rotenone, and the ETC complex III inhibitor antimycin A were carried out.
(legend continued on next page)
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dria (Figure 5E). These data indicate that TRAP1 limits maximal
respiration by acting at ETC complex II. We also found that
3-NP inhibits death in a dose-dependent fashion in shTRAP1,
but not in mock SAOS-2 cells placed in conditions of long-
term starvation that mimic the paucity of nutrients found in the
inner tumor mass during the phases of its rapid accrual (Fig-
ure 5F). Moreover, treatment with 3-NP partially restored the
ability of shTRAP1 cells to form colonies in soft agar, whereas
it was ineffective on the colonies formed by control cells
(Figure 5G).
TRAP1 Induces Succinate Accumulation and HIF1a
Stabilization, which Is Required for Tumor Cell Growth
It was shown that succinate induces HIF1 by inhibiting PHDs, the
enzymes that hydroxylate HIF1a, allowing its subsequent ubiqui-
tin-dependent degradation (Selak et al., 2005). We observed that
during the focus-forming assay, the intracellular level of succi-
nate increased only in TRAP1-expressing cells (Figure 6A),
matching the downmodulation of their SDH enzymatic activity
(Figure 4B). In keeping with these results, HIF1a was detectable
exclusively in TRAP1-expressing cells during the focus-forming
process (Figure 6B), whereas it was hydroxylated on Pro resi-
dues (i.e., primed for proteasomal degradation) both in culture
conditions, independently of the presence of TRAP1, and in
shTRAP1 cells exposed to focus-forming conditions (Figure 6C).
HIF2a, which shares some redundant functions with HIF1a and
whose expression is increased in a broad spectrum of cancer
cell types (Keith et al., 2012), was not stabilized in our experi-
mental conditions (Figure 6D). We then used pimonidazole, a
compound that is reductively activated under hypoxic conditions
and forms protein adducts by reacting with Cys residues (Arteel
et al., 1998), to understand whether HIF1a stabilization could at
least partially depend on hypoxic conditions occurring during the
formation of foci. Remarkably, we could not detect any induction
of pimonidazole-protein adducts in TRAP1-expressing cells dur-
ing the process of in vitro tumorigenesis, even when HIF1a had
already been stabilized (Figure 6E), which demonstrates that
pseudohypoxic conditions elicited by the presence of TRAP1
are sufficient to promote HIF1a stabilization. Tumor samples
obtained from nude mice xenografted with TRAP1-expressing
SAOS-2 cells (see Figure 1D) were characterized by densely
packed cells, amidst which fibrotic and necrotic areas could
be observed (Figure 6F, marked as F and N, respectively);(B) ATP levels were measured in mock or shTRAP1 SAOS-2 cells kept in standard
1–2 days before cells that did not form foci massively underwent death (bars on
inhibitor oligomycin or the hexokinase inhibitor 5-thioglucose (5TG) in a no-glu
glycolysis.
(C and D) Representative traces of OCR experiments performed on monolayers of
(E) Analysis of the effect of the SDH inhibitor 3-NP on the SQR enzymatic activity o
starting recordings; 10 mM 3-NP was used to fully inhibit the SDH enzyme.
(F) Cytofluorimetric cell death analysis of SAOS-2 cells starved in a medium witho
cells are identified as double negative for propidium iodide and Annexin V-FITC.
(G) Soft agar assay on SAOS-2 cells. Data are reported as fold increase of colony
drug (left) and, separately, as fold increase of colony area of shTRAP1 cells gro
SAOS-2 experiments, mock indicates cells stably transfected with a scramble
shTRAP1 + mTRAP1 indicates cells stably transfected with a TRAP1 shRNA and
stably transfected with either a TRAP1 cDNA or a scrambled shRNA (mock). All
analysis.
994 Cell Metabolism 17, 988–999, June 4, 2013 ª2013 Elsevier Inc.HIF1a was clearly detected in the majority of cells, the signal
being particularly strong in the nuclei of cells where proliferation
markers were also evident (compare theMIB/Ki67 and the HIF1a
staining in Figure 6F). In these samples, cells displayed a punc-
tate TRAP1 signal that fits well with its mitochondrial localization
(see the high-magnification TRAP1 staining in Figure 6F). The
addition of dimethyl succinate, a membrane-permeable succi-
nate analog, to the focus-forming culturemedium both stabilized
HIF1a (Figure 7A) and rescued the capability to form colonies
(Figure 7B) in shTRAP1 cells, while it did not further increase
the tumorigenicity of TRAP1-expressing cells (Figure 7B). More-
over, HIF1a inhibition either with a cell-permeable esterified
form of a-ketoglutarate (1-trifluoromethylbenzyl-a-ketogluta-
rate, TaKG), which reverses HIF1a stabilization by restoring
PHD enzymatic activity (MacKenzie et al., 2007; Tennant et al.,
2009), or with RNAi on HIF1a or HIF1b, the latter being the stable
subunit of the heterodimeric HIF transcription factors (Keith
et al., 2012), fully abolished formation of foci in TRAP1-express-
ing tumor cells and in MEFs transfected with a TRAP1 cDNA
(Figures 7C–7F). Taken together, these data indicate that
TRAP1 prompts neoplastic growth by inducing a succinate-
dependent stabilization of HIF1a.
DISCUSSION
Tumor cells tend to increase their glycolytic activity without a
matching increase of oxidative phosphorylation (Warburg,
1956; Warburg et al., 1927). Inhibition of the tumor suppressor
p53 or activation of the transcription factor HIF1 curtails
OXPHOS by inducing the autophagic degradation of respiratory
complexes and by abrogating the synthesis of some of their sub-
units (such as SDHB) or assembly factors (Denko, 2008;
Semenza, 2010a; Vousden and Ryan, 2009). Conversely,
OXPHOS inhibition can play a causal role in tumorigenesis. Inac-
tivating mutations in mitochondrial DNA (mtDNA) genes encod-
ing for subunits of ETC complexes I and III were found associ-
ated with renal oncocytomas (Gasparre et al., 2008) as well as
thyroid and prostate cancers (Abu-Amero et al., 2005; Petros
et al., 2005). However, these mutations are confined to a small
set of neoplasms, and the lack of clear-cut molecular mecha-
nisms hampers the definition of whether OXPHOS inhibition as
such can play a general tumorigenic role. Key findings of
the present work demonstrate that the mitochondrial chap-
erone TRAP1, which is widely expressed in most tumors, butculture conditions (bars on the left) or in a focus-forming assay for 15 days (i.e.,
the right). Where indicated, cells were treated for 2 hr with the ATP synthase
cose medium to discriminate between ATP produced by OXPHOS and by
living MEF cells (C) or SAOS-2 cells (D). Experiments were carried out as in (A).
f complex II in mitochondria from SAOS-2 cells. 3-NP was added 5 min before
ut serum for 96 hr with or without the reported concentrations of 3-NP. Viable
area of mock cells grown with 3-NP compared with mock cells kept without the
wn with 3-NP compared with shTRAP1 cells kept without the drug (right). In
d shRNA; shTRAP1 indicates cells stably transfected with a TRAP1 shRNA;
expressing a mouse TRAP1 cDNA. In the experiment with MEFs, cells were
bar graphs report mean ± SD values (nR 3); *p < 0.01 with a Student’s t test
Figure 6. TRAP1 Increases Intracellular Succinate Concentration and Stabilizes HIF1a in a Hypoxia-Independent Way
(A) Bar graphs showing liquid chromatography-mass spectrometry (LC-MS) measurements of intracellular succinate level. Values are compared with cultured
mock SAOS-2 cells.
(B–D) Western immunoblots showing HIF1a expression (B), HIF1a hydroxylation of the Pro402 and Pro564 residues (C), and HIF2a expression in cultured cells
and on extracts from focus-forming assays obtained at the 15th experimental day (i.e., 1–2 days before cells that did not form foci massively underwent death).
CoCl2 is used as a positive control for HIF1a and HIF2a stabilization. Blots were probed with an anti-actin (B) or an anti-GAPDH (C and D) antibody to check for
protein load.
(E) Detection of pimonidazole-protein adducts in SAOS-2 mock cells kept in either normal culture or focus-forming conditions for 10 or 15 days. Pimonidazole
(200 mM) was added on the focus-forming plate 2 hr before lysis. As a positive control, cells were kept for 24 hr in a hypoxic chamber (0.5% O2). On
(legend continued on next page)
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TRAP1 Promotes Neoplastic Growth by Inhibiting SDHnot in highly proliferating, nontransformed cells (http://www.
proteinatlas.org/), is a component of the molecular machinery
that decreases mitochondrial respiration and that this event is
crucial for neoplastic progression. Indeed, we find that TRAP1
behaves as an oncogene since (i) without TRAP1, tumorigenesis
is blunted both in vitro and in vivo, and (ii) TRAP1 expression con-
fers tumorigenic potential to nontransformed cells. We observe
that TRAP1-mediated inhibition of SDH limits the maximal rate
of respiration and leads to succinate accumulation followed by
HIF1a, but not HIF2a, stabilization. Remarkably, the mem-
brane-permeable succinate analog dimethyl succinate could
both elicit HIF1a stabilization and rescue the tumorigenic pheno-
type of shTRAP1 cells, highlighting the mechanistic connec-
tion between TRAP1-dependent succinate accumulation and
HIF1a-dependent tumor formation.
The role played by the transcription factor HIF1 in tumorigen-
esis is complex. Once activated by inhibition of the proteasomal
degradation of its a subunit (either HIF1a or HIF2a), and by the
ensuing association with the stable b subunit (HIF1b), HIF1 can
boost evolution of neoplasms by promoting angiogenesis,
epithelial-mesenchymal transition, and the glycolytic switch
(Brahimi-Horn et al., 2011; Semenza, 2010a). In multiple tumor
models, both HIF1a and HIF2a promote neoplastic progression
by regulating sets of genes that are only partially shared, and
independent roles for HIF1a and HIF2a can depend on the can-
cer type or on its growth and progression stages (Keith et al.,
2012). However, both a subunits can play a tumor suppressor
function in specific tumor types, such as renal cell carcinoma
(HIF1a) or lung adenocarcinoma (HIF2a), through poorly
defined mechanisms. In our model, HIF1a stabilization, and
the ensuing HIF activation, have a crucial proneoplastic role,
as promoting HIF1a degradation or knocking down either
HIF1a or HIF1b abolishes the neoplastic potential of TRAP1-
expressing cells. Instead, we could not observe any HIF2a
stabilization, ruling out its role in the TRAP1-dependent tumor-
igenic process. It is interesting that HIF2a accumulates at
higher O2 concentrations than HIF1a (Keith et al., 2012), and
the possibility exists that, at variance with what we observe
for HIF1a, pseudohypoxic conditions are insufficient or unable
to stabilize HIF2a.
HIF1a stabilization emerges after several days of in vitro trans-
formation. This is not at all surprising because excess succinate
can be utilized in multiple pathways, including increased heme
synthesis (Frezza et al., 2011), and because SDH becomes
more strongly inhibited by TRAP1 during the focus-forming
assay. The latter observation also suggests that a threshold
SDH inhibition must be reached to allow for succinate accumu-
lation. Despite a partial respiratory inhibition, TRAP1-expressing
cells fully utilize their residual respiratory capacity to produce
ATP, as shown by OCR experiments, but reorient their meta-
bolism toward glycolysis to meet any energy demand thatthe same samples, both HIF1a stabilization and the expression level of TRA
protein load.
(F) Immunohistochemical inspections of tumors formed by SAOS-2 control cells
Azan-Mallory staining reveal tumors rich in densely packed cells, with few fibrotic
cells (see the 6.253magnification) as a punctate signal (1003magnification), whic
all along the samples (see the 6.253 magnification), mainly in the nuclear compa
perinecrotic areas, where the proliferation marker MIB-1/Ki67 is also found (253
996 Cell Metabolism 17, 988–999, June 4, 2013 ª2013 Elsevier Inc.exceeds respiratory capacity, in complete accord with War-
burg’s observations.
TRAP1 is likely to begin a feedforward loop, as it inhibits SDH
and respiration (henceOXPHOS) and induces HIF1, which in turn
further inhibits OXPHOS (Denko, 2008; Semenza, 2010b) and
directly downregulates SDH by induction of miR-210 (Puisse´gur
et al., 2011). Notably, we have determined that TRAP1-depen-
dent stabilization of HIF1a occurs in a pseudohypoxic way (i.e.,
in the absence of any hypoxic stress). This observation has
potential implications for the kinetics of tumor development, as
TRAP1 could induce HIF1 transcriptional activity even before
the dysregulated accrual of the tumor mass creates hypoxic
areas in its inner core.
At variance with the complete block of the SDH enzyme, which
is an extreme case caused by loss-of-function mutations only
seen in specific subsets of tumors (Bardella et al., 2011), the par-
tial and reversible SDH inhibition caused by TRAP1 and its
increased expression levels would mediate a more general pro-
neoplastic function, which fits with TRAP1 identification as a
bona fide inducible target of the proto-oncogene c-Myc (Coller
et al., 2000).
Tumor cells could be endowed with a multichaperone mito-
chondrial complex, as TRAP1 interacts with cyclophilin D,
Hsp90, and Hsp60 (Ghosh et al., 2010; Kang and Altieri, 2009).
Given the multiplicity of chaperone client proteins, we cannot
exclude further interactions of TRAP1 with other mitochondrial
components. For instance, TRAP1 is involved in the inhibition
of the mitochondrial permeability transition pore (Kang et al.,
2007), whose opening irreversibly commits cells to death (Rasola
and Bernardi, 2007; Rasola et al., 2010b), and we have observed
that keeping the pore locked can be used by tumor cells to evade
apoptosis (Rasola et al., 2010a). Thus, TRAP1 could take part in
several mitochondrial changes that crucially contribute to the
neoplastic phenotype. Targeting its chaperone activity and
molecular interactors could dismantle the metabolic and survival
adaptations of neoplastic cells, paving the way to the develop-
ment of highly selective, mitochondriotropic antineoplastic
drugs.EXPERIMENTAL PROCEDURES
Detailedmethods can be found in the Supplemental Experimental Procedures.
Cell Cultures and Tissue Samples
Experiments were performed on different cell models: human SAOS-2 osteo-
sarcoma cells, human HCT116 colorectal carcinoma cells, RWPE1/RWPE2
prostate epithelial cells, HeLa cervix carcinoma cells, and MEFs. TRAP1,
HIF1a, and HIF1b expression was knocked down by stable transfections
with shRNAs. Cells transfected with scrambled shRNA were always used as
controls. TRAP1 re-expression in interfered human cells was obtained by
using a mouse cDNA. Stable transfection of a TRAP1 cDNA was performed
in MEF cells that show negligible levels of the endogenous protein. TissueP1 were evaluated; blots were probed with an anti-GAPDH to check for
after injection in nude mice (see Figure 1F). Hematoxylin and eosin (H&E) and
areas (F) and a large number of necrotic regions (N). TRAP1 is visible in most
h is compatible with its mitochondrial localization. HIF1a expression is evident
rtment of cells (1003 magnification), and the signal is particularly strong in the
magnification).
Figure 7. TRAP1 Favors Tumor Growth
through Succinate-Dependent Stabilization
of HIF1a
(A) Western immunoblot showing HIF1a stabiliza-
tion in SAOS-2 cells kept either in culture or in
focus-forming conditions in the presence of the
cell-permeable succinate analog dimethyl succi-
nate (20 mM, 48 hr). Extracts from focus-forming
assays were obtained at the 15th experimental day
(i.e., 1–2 days before cells that did not form foci
massively underwent death). Blots were probed
with an anti-GAPDH to check for protein load.
Cells are dubbed as in previous figures with
respect to TRAP1 expression.
(B) Soft agar experiments performed on SAOS-2
cells treated with dimethyl succinate (5 mM). Data
indicate the total colony area at the 25th experi-
mental day.
(C–F) Focus-forming assays on SAOS-2 cells (C) or
MEFs (D) grown with or without TaKG and on
SAOS-2 cells in which HIF1a (E) or HIF1b (F)
expression had been knocked down byRNAi. Data
are reported as in Figure 1A. In (E), CoCl2 treatment
is used to maximize HIF1a expression. In (F),
knocking down of HIF1b is obtained with a mixture
of three different shRNAs. Bar graphs report
mean ± SD values (n R 3); *p < 0.01 with a
Student’s t test analysis. Cells are dubbed as in
previous figures.
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TRAP1 Promotes Neoplastic Growth by Inhibiting SDHsamples from both tumor and normal, noninfiltrated peritumoral mucosa were
obtained from patients with colorectal carcinoma during surgical cancer
removal after express written informed consent was obtained from all patients.
Tumorigenesis Assays
Three different tumorigenesis assays were performed: (1) focus-forming
assays, in which cells were grown to confluence and kept in culture for the sub-
sequent 25 days; tumor cells lose contact inhibition and overgrow to form foci;Cell Metabolism 17, 988–(2) soft agar assays, in which cells are embedded
in an agar matrix; only transformed cells, which
escape anoikis death signals, can grow to form
colonies; (3) cell injection in nude mice, in order
to follow the growth of primary tumors. Samples
obtained from these assays were also exploited
for investigating changes in complex II enzymatic
activity in succinate levels and in HIF1a stabiliza-
tion and distribution.
Cytofluorimetric Analyses
Cytofluorimetric analyses were utilized to analyze
cell death induction with the use of Annexin V-
FITC and propidium iodide probes as well as mito-
chondrial mass with the use of N-acridine orange.
Mitochondria Purification
Mitochondria were isolated through sequential
centrifugations after mechanical cell disruption.
In order to establish submitochondrial protein
localization, isolated mitochondria were partially




Western immunoblot and immunoprecipita-
tion experiments were performed following stan-dard techniques. BN-PAGE experiments were carried out on isolated
mitochondria in order to identify ETC complexes. After a first elec-
trophoresis in nondenaturing conditions, bands were visualized with
Coomassie blue staining, cut, and run on SDS-PAGE for the identi-
fication of protein components by western immunoblot. Crosslinking
assays were performed on isolated mitochondria incubated with the
membrane-permeable, homobifunctional reagent DTBP prior to TRAP1
immunoprecipitation.999, June 4, 2013 ª2013 Elsevier Inc. 997
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TRAP1 Promotes Neoplastic Growth by Inhibiting SDHETC Complex II Activity Assays and Oxygen Consumption Rate
Experiments
Complex II enzymatic activity was investigated, measuring the SQR activity
with classical spectrophotometric approaches on cell or tumor lysates. Com-
plex IV enzymatic activity was investigated, measuring the oxidation of
reduced cytochrome c. Each measurement of the respiratory chain (RC)
complex activity was normalized for protein amount and for citrate synthase
activity. In vivo respiration was followed in a kinetic mode by measuring the
oxygen consumption rate (OCR) of cell monolayers with an extracellular flux
analyzer.
Immunohistochemical and Immunoelectron Microscopy Analyses
Immunohistochemical inspections were performed on serial sections of
paraffin-embedded tumor samples obtained from xenografted nude mice
following standard procedures. Immunoelectron microscopy (immuno-EM)
inspections were performed on antibody-labeled fixed cells using the gold-
enhanced protocol.
Determination of Intracellular Succinate Level
Intracellular succinate level was analyzed on lysates obtained by scraping
cells placed in a cold methanol/acetonitrile solution. After spinning down
the insoluble material, the supernatant was collected, and metabolites
were separated using a liquid chromatography system coupled online to an
LTQ Orbitrap mass spectrometer equipped with an electrospray ionization
source.
Intracellular ATP Determination
Intracellular ATP was quantified by the luciferin/luciferase method. Cells were
kept for 2 hr in the different experimental conditions.
Statistical Analysis
Student’s t test was used to compare pairs of data groups. In all figures, bar
graphs report mean ± SD values (nR 3); *p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2013.04.019.
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